Congenital Myasthenic Syndrome Clinical Trial
Official title:
A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes
The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function. After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the treatment period. Participants will then enter the follow-up period. The full duration of the study is approximately 11 months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01203592 -
Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
|
Phase 1 | |
| Recruiting |
NCT01403402 -
Congenital Muscle Disease Study of Patient and Family Reported Medical Information
|
||
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Completed |
NCT01474980 -
Pregnancy Outcomes in Congenital Myasthenie Syndrome
|
N/A | |
| Recruiting |
NCT06078553 -
A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)
|
||
| Approved for marketing |
NCT00872950 -
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
|
||
| No longer available |
NCT03062631 -
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
|
||
| No longer available |
NCT02189720 -
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
|